Hillsdale Investment Management Inc. Takes Position in Bausch Health Cos Inc. $BHC

Hillsdale Investment Management Inc. bought a new stake in shares of Bausch Health Cos Inc. (NYSE:BHC) in the fourth quarter, Holdings Channel reports. The fund bought 524,892 shares of the company’s stock, valued at approximately $3,651,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of BHC. Dynamic Technology Lab Private Ltd bought a new position in shares of Bausch Health Cos during the 1st quarter valued at approximately $68,000. Jones Financial Companies Lllp grew its position in shares of Bausch Health Cos by 1,548.9% during the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock valued at $162,000 after acquiring an additional 23,451 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Bausch Health Cos by 97.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock valued at $6,136,000 after acquiring an additional 467,270 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Bausch Health Cos by 3.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock valued at $2,102,000 after acquiring an additional 9,834 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Bausch Health Cos by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock valued at $5,597,000 after acquiring an additional 84,892 shares during the period. 78.65% of the stock is owned by institutional investors.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the sale, the director directly owned 49,339 shares in the company, valued at $267,910.77. This represents a 33.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by corporate insiders.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $5.37 on Monday. The stock has a market capitalization of $2.01 billion, a P/E ratio of -1.66 and a beta of 0.40. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68. The firm’s 50 day moving average is $5.46 and its 200 day moving average is $6.07. Bausch Health Cos Inc. has a 12 month low of $4.41 and a 12 month high of $8.69.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. On average, sell-side analysts anticipate that Bausch Health Cos Inc. will post 4.08 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on BHC. Barclays reduced their target price on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen cut shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Weiss Ratings cut shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Finally, Royal Bank Of Canada dropped their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $8.00.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.